U.S. pharmacy operator CVS Health Corp. made an offer to acquire No. 3 U.S. health insurer Aetna Inc. for more than $200 per share, or over $66 billion, sources said.
Endo International Plc said two units filed a lawsuit accusing the U.S. Food and Drug Administration of ignoring key components of a law passed after a deadly 2012 meningitis outbreak linked to a compounding pharmacy.
Outcome Health announced a partnership with Navicent Health. The partnership will bring the Outcome Health platform to Navicent Health Physicians Group, which includes over 100 active physicians and their medical/surgical practices.
During a fireside chat at BIO International in San Diego in summer 2017, Daniel Skovronsky – now president of Lilly Research Labs – confirmed Eli Lilly’s commitment to finding an effective therapy for Alzheimer’s disease. Lilly continues to push forward. EP Vantage highlighted and analyzed the company’s five Phase I programs for Alzheimer’s disease. Much like what Skovronsky said about learning from the Phase III solanezumab failure, EP Vantage pointed to some of the hopes the Lilly programs have for blocking the development of amyloid plaques.
AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster Humira or J&J’s Stelara in treating moderate-to-severe chronic plaque psoriasis.
In the company’s third-quarter 2017 report, Amgen Inc. announced it scrapped internal development of AMG 899, an oral CETP inhibitor it acquired in the $1.2 billion deal for Netherlands-based Dezima Pharma BV.
The billionaire founder of Insys Therapeutics Inc. was arrested on U.S. charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.
Trump declares opioid epidemic a public health emergency; crisis could spread to Europe, experts say
As U.S. President Donald Trump declared the opioid crisis a public health emergency, Europe should heed the threat from opioids responsible for America’s deadliest drug epidemic in decades as both regions have seen rises in prescription rates of such medicines, which can be a gateway to dangerous derivatives according to experts.
GlaxoSmithKline’s new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain’s biggest drugmaker. Emma Walmsley wants to boost the core pharmaceuticals division and also bulk up GSK’s big consumer healthcare operation, a twin-track strategy that could strain finances and has fueled fears for the dividend.